Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial.

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut. 2014 Nov; 63(11):1721-7.

View in: PubMed

subject areas

Adolescent
Adult
Aged
Antibodies, Monoclonal
Area Under Curve
C-Reactive Protein
Crohn Disease
Female
Humans
Infliximab
Male
Middle Aged
Remission Induction
Retrospective Studies
Treatment Outcome
Young Adult

authors with profiles

Stephen B. Hanauer